Cellectis and Lonza Agree on Manufacturing for UCART Cell Therapies
Cellectis and Lonza have entered into an agreement for the clinical manufacturing of Cellectis' UCART product candidates. Manufacturing will take place at Lonza's facility in the Netherlands.
Cellectis, a biopharmaceutical company developing immunotherapies, and Lonza have signed a manufacturing service agreement for Cellectis' allogeneic gene-edited CAR T-cell (UCART) product candidates. The deal focuses on the clinical manufacturing of therapies targeting hematological malignancies.
Production will be carried out at Lonza's current Good Manufacturing Practices (cGMP) facility located in Geleen, Netherlands. Lonza will implement Cellectis' manufacturing processes, adhering to stringent quality and safety standards set by the FDA.
Cellectis' UCART therapies are based on allogeneic, or "off-the-shelf," cells that are genetically engineered to identify and destroy cancer cells. The company is developing these cell therapies primarily for the treatment of blood cancers.
This agreement aims to ensure a reliable supply of high-quality therapies for ongoing clinical trials. While Cellectis has developed its own manufacturing processes previously, this collaboration with Lonza is expected to enhance its global manufacturing capabilities.